Gilead: Analysts' Upgrades, Downgrades

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Amgen (AMGN) rated new Hold at Deutsche Bank. $57 price target. Do not expect a positive phase-3 trial for Dmab bone drug.

Atmel (ATML) downgraded at FBR from Outperform to Market Perform. $6.75 price target. Supply-chain inventories are building up faster.

Biogen Idec (BIIB) rated new Hold at Deutsche Bank. $57 price target. Company is facing potential new competition.

Chesapeake Energy (CHK) upgraded at BMO to Outperform. Valuation call, based on a $30 price target.

CenterPoint (CNP) reinstated at BofA/Merrill with a Buy rating and $17 price target. Long term growth story driven by expansion projects and its utilities.

Dendreon (DNDN) rated new Buy at Deutsche Bank. $44 price target. Provenge supply overhang should soon be removed, and the company has large potential to grow in Europe.

Emdeon (EM) upgraded at Wells to Outperform. Valuation call, as the stock is down 30% year-to-date.

The Geo Group (GEO) reinstated at Barclays with an Overweight rating and $26 price target. CRN merger adds scale and inventory at a good price.

Gilead (GILD) rated new Buy at Deutsche Bank. $42 price target. At least one of the company's HIV drugs in the pipeline should come to market.

Intercontinental Exchange (ICE) upgraded at Credit Suisse to Outperform from Neutral. Valuation call. Fundamentals remain best in class. Maintain $125 price target.

Perfect World (PWRD) downgraded at ThinkEquity from Buy to Hold. $27 price target. Don't see much growth potential from current games and margins could come under pressure.

VMWare (VMW) upgraded at ThinkEquity from Hold to Buy. $90 price target. Growth in the virtualization business should continue to accelerate.

STOCK COMMENTS / EPS CHANGES

Brocade (BRCD) target cut at Jefferies. BRCD target was reduced to $6. OEM inventory correction could lead to lumpy results. Hold rating.

Salesforce.com (CRM) target upped at Jefferies to $86. Company should report a good quarter and currency trends have been improving. Hold rating.

Cintas (CTAS) estimates lowered at Morgan Stanley. CTAS estimates were cut through 2013. Company is facing increased competition. Equal-weight rating and $27 price target.

Corrections Corp of America (CXW) price target raised at Barclays by a dollar to $26 on solid 2011 guidance. Maintain Overweight rating.

Deere (DE) estimates, target raised at Citigroup. Shares of DE now seen reaching $75. Estimates also increased, as commodity prices and costs are working in the company's favor. Buy rating.